The DOI matches its Crossref record.
Porphyrin-based Sensitizers in the Detection and Treatment of Cancer: Recent Progress
Abstract
It has been known for some time that porphyrins and related compounds have the ability to selectively accumulate in tumor tissues, and to persist there for long periods of time. This property, along with the well-described photophysical and photosensitizing properties of porphyrin-type molecules, has led to their potential use as adjuvants and sensitizers in a variety of medical applications, such as in photodynamic therapy (PDT), boron neutron capture therapy (BNCT), radiation therapy (RT) and in magnetic resonance imaging (MRI). Both PDT and BNCT are binary cancer therapies that involve activation of tissue-localized sensitizers with either light (in PDT) or low-energy neutrons (in BNCT). In both of these therapeutic methodologies, local tumor control with minimal side effects relative to other forms of cancer treatment (surgery, radiotherapy, chemotherapy) can be achieved. Porphyrins constitute a major class of pharmacological agents currently under investigation. Photofrin, a porphyrin derivative, has been approved in the USA as a PDT drug by the U.S. Food and Drug Administration (FDA), and also in Japan, Canada and in eleven European countries. Recently, the FDA approved Visudyne, another porphyrin derivative for the PDT treatment of the 'wet-form' of age-related macular degeneration. In addition to cancer treatment porphyrins are also under investigation for application in the treatment of a variety of other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Plasmonic photothermal therapy (PPTT) using gold nanoparticles
Huang, X., Jain, P. K., El-Sayed, I. H., & El-Sayed, M. A. (2008) · Lasers in Medical Science · doi:10.1007/s10103-007-0470-x · Cited by 2,376
Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects
Barth, R. F., Coderre, J. A., Vicente, M. G. H., & Blue, T. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0035 · Cited by 1,046
Self-citationDye Sensitizers for Photodynamic Therapy
Ormond, A., & Freeman, H. (2013) · Materials · doi:10.3390/ma6030817 · Cited by 847
Photodynamic therapy (PDT) of cancer: from local to systemic treatment
Dabrowski, J. M., & Arnaut, L. G. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c5pp00132c · Cited by 501
Dąbrowski, J. M., Pucelik, B., Regiel-Futyra, A., Brindell, M., Mazuryk, O., Kyzioł, A., Stochel, G., Macyk, W., & Arnaut, L. G. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.06.007 · Cited by 317
Metadata
- Authors
- Vicente, M.
- Venue
- Current Medicinal Chemistry-Anti-Cancer Agents
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2001-08-01
- Volume
- 1
- Issue
- 2
- Pages
- 175-194
- ISSN
- 1568-0118 (ISSN-L)
- OpenAlex
- W2049554577
- Cited by
- 221
- References
- 0
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Porphyrin-based Sensitizers in the Detection and Treatment of Cancer: Recent Progress. https://app.cochat.ai/papers/10.2174/1568011013354769
- The paper
- Vicente, M. (2001). Porphyrin-based Sensitizers in the Detection and Treatment of Cancer: Recent Progress. Current Medicinal Chemistry-Anti-Cancer Agents. https://doi.org/10.2174/1568011013354769
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.